Adrenal Insufficiency

Rhythm Pharmaceuticals announced positive results from two phase 3 clinical trials evaluating setmelanotide, a melanocortin-4 receptor agonist for the treatment of rare congenital forms of obesity, according to a company press release.

Adults with bilateral pheochromocytomas treated with cortical-sparing adrenalectomy were less likely to need steroid replacement therapy and had a low risk for tumor recurrence over 8 years when compared with similar patients who underwent total bilateral adrenalectomy, according to a retrospective database analysis published in JAMA Network Open.